

finasteride in the air above an opened bottle of finasteride suspension following shaking. However, we can state that any exposure would not be more than 3.7 µg/1000 L (64.3% of the LOD) of room air. Nevertheless, since current regulations are based on “no safe limit” of exposure of any hazardous drug to any person (patient or staff) not prescribed the drug, the use of PECs and PPE are strongly recommended when handling hazardous drugs to minimize the risk of cutaneous or respiratory exposure to powders or miniscule quantities of vapors not quantified by our study.<sup>1,2</sup> We continue to test this hypothesis to demonstrate safe handling of other hazardous drugs.

## Conclusion

We conclude that formulations of finasteride in water, OM, and OM SF are stable for at least 90-days when stored at room temperature or 4°C, retaining more than 94.3% after 90 days of storage, with more than 95% confidence. A suspension of finasteride can be compounded without crushing the tablets by simply dropping tablets into the suspending vehicle and shaking vigorously for 30 seconds every 5 minutes for 1 hour. Although we could not detect finasteride in room air, given the analytical limits of the study, we estimate that exposure is not likely to exceed 3.7 µg/1000 L of room air. Nevertheless, since current regulations are based on “no safe limit,” the use of PECs and PPE as appropriate are recommended.

## References

1. Department of Health and Human Services. Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. *NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings*, 2014. [CDC Website.] Available at: [www.cdc.gov/niosh/docs/2014-138/pdfs/2014-138.pdf](http://www.cdc.gov/niosh/docs/2014-138/pdfs/2014-138.pdf). Accessed October 22, 2020.
2. Centers for Disease Control and Prevention. National Institute for Occupational Safety and Health. *Hazardous Drugs: Draft NIOSH List of Hazardous Drugs in Healthcare Settings, 2020; Procedures; and Risk Management Information*. [CDC Website.] Available at: [www.cdc.gov/niosh/docket/review/docket233c/default.html](http://www.cdc.gov/niosh/docket/review/docket233c/default.html). Accessed October 22, 2020.
3. Merck Canada Inc. Proscar [product monograph]. [Merck Canada Website.] Available at: [www.merck.ca/en/home](http://www.merck.ca/en/home). Accessed March 19, 2014.
4. Syed AA, Amshumali MK. LC determination of finasteride and its application to storage stability studies. *J Pharm Biomed Anal*. 2001; 25(5–6): 1015–1019.
5. Segall A, Vitale MF, Perez VL et al. A stability-indicating HPLC method to determine finasteride in a tablet formulation. *J Liq Chromatography Related Technol*. 2002; 25(20): 3167–3176.
6. Srinivas G, Kumar KK, Reddy YR et al. A validated stability indicating LC method of assay and related substances for finasteride. *J Chem Pharm Res*. 2011; 3(6): 987–996.
7. Reis RH, Paula FR, Machado MM et al. Stability study of finasteride: Stability-indicating LC method, in silico and LC-ESI-MS analysis of major degradation product, and an *in vitro* biological safety study. *J Chromatogr Sci*. 2018; 56(6): 531–540.
8. Shah VP, Midha KK, Dighe S et al. Analytical methods validation: Bioavailability, bioequivalence and pharmacokinetic studies: Sponsored by the American Association of Pharmaceutical Chemists, U.S. Food and Drug Administration, Fédération Internationale Pharmaceutique, Health Protection Branch (Canada) and Association of Official Analytical Chemists. *Int J Pharmaceutics*. 1992; 81(1–2): 1–7.
9. United States Pharmacopeial Convention, Inc. *United States Pharmacopeia 40–National Formulary 35*. Rockville, MD: United States Pharmacopeial Convention, Inc.: 2017.
10. Al-Gousous J, Langguth P. Oral solid dosage form disintegration testing – The forgotten test. *J Pharm Sci*. 2015; 104(9): 2664–2675.
11. Silva DL, Webster GK, Bou-Chacra N et al. The significance of disintegration testing in pharmaceutical development. *Dissolution Technologies*. 2018; 30–38.
12. Frieman JA, Chalmers TC, Smith H Jr. et al. The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 “negative” trials. *N Engl J Med*. 1978; 299(13): 690–694.
13. Stolley PD, Strom BL. Sample size calculations for clinical pharmacology studies. *Clin Pharmacol Ther*. 1986; 39(5): 489–490.
14. Trissel LA. Avoiding common flaws in stability and compatibility studies of injectable drugs. *Am J Hosp Pharm*. 1983; 40(7): 1159–1160.
15. Trissel LA, Flora KP. Stability studies: Five years later. *Am J Hosp Pharm*. 1988; 45(7): 1569–1571.
16. [No author listed.] Policy for publication of chemical stability study manuscripts. *Can J Hosp Pharm*. 1997.
17. National Library of Medicine. PubChem. Finasteride [product information]. [NIH Website.] Available at: <https://pubchem.ncbi.nlm.nih.gov/compound/finasteride#section=Experimental-Properties>. Accessed October 22, 2020.

Address correspondence to Scott E. Walker, MScPhm, Department of Pharmacy, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5. E-mail: [scott.walker@sunnybrook.ca](mailto:scott.walker@sunnybrook.ca) ✓

## Erratum

Stability of Extemporaneous Oral Tramadol, Fluoxetine, and Doxycycline Suspensions in SyrSpend SF PH4. *IJPC*. 2020; 24(4): 327; Abstract, 3rd line from bottom, should read: “...doxycycline (2 mg/mL to 50 mg/mL) was stable...” The concentration is correct in the remainder of the article.